Cohance's CEO's exit triggers leadership overhaul; Chairman Vivek Sharma takes full control. (Photo source: Freepik) Cohance’s Q2 FY26 performance was in line with brokerage's expectations, though the cut in FY26 guidance was disappointing. While pharma CDMO growth continues to be impacted by inventory destocking for two products, dip in sales of NJ Bio and API+ (-4% YoY) division was a surprise.

To continue reading this story You must be an existing Premium User Already a Premium User? Sign In

See Full Page